|
Mitchell, M S; Jakowatz, J; Harel, W et al. (1994) Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 12:402-11
|
|
Mitchell, M S; Liggett, P E; Green, R L et al. (1994) Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol 12:396-401
|
|
Quan Jr, W D; Mitchell, M S (1993) Immunology and immunotherapy of melanoma. Cancer Treat Res 65:257-77
|
|
Kan-Mitchell, J; Huang, X Q; Steinman, L et al. (1993) Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 37:15-25
|
|
Mitchell, M S; Harel, W; Kan-Mitchell, J et al. (1993) Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci 690:153-66
|
|
LeMay, L G; Kan-Mitchell, J; Goedegebuure, P et al. (1993) Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol Immunother 37:187-94
|
|
Mitchell, M S (1992) Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol 19:80-7
|
|
Mitchell, M S (1992) Biomodulators in cancer treatment. J Clin Pharmacol 32:2-9
|
|
Mitchell, M S (1992) Principles of combining biomodulators with cytotoxic agents in vivo. Semin Oncol 19:51-6
|
|
Mitchell, M S; Harel, W; Groshen, S (1992) Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10:1158-64
|
Showing the most recent 10 out of 28 publications
